Untapped Possibilities of Antiischemic Therapy after Acute Myocardial Infarction: Data from the PROFILE-IM Register

Aim. To evaluate the practice of prescribing antianginal/antiischemic therapy in patients who, after acute myocardial infarction (AMI), retained typical clinical manifestations of stable angina.

Material and methods. The registry includes 160 patients who applied to the polyclinic from March 01, 2014 to June 30, 2015 after suffering an AMI. Anti-ischemic therapy was evaluated in patients with typical angina pectoris.

Results. Based on the survey, typical angina attacks were detected in almost a quarter of patients (38 patients – 23.8%). According to the main indicators, patients with typical angina pectoris practically did not differ from the rest of the group of patients, with the exception of a significantly larger proportion of patients with diagnosed ischemic heart disease before AMI and patients under dispensary supervision. Almost all patients received beta-blockers (97.4%), about a third of patients received calcium antagonists (28.9%) or long-acting nitrates (34,2%). During the first year after AMI, second-line drugs were practically not prescribed to enhance antianginal therapy. According to international non-proprietary names, the choice of doctors tended to prescribe bisoprolol, amlodipine, and isosorbide dinitrate. Exacerbation of the disease course with hospitalization for unstable angina pectoris was recorded in 9 (23.7%) patients from the group with typical angina pectoris and in 5 (4.1%) patients in the rest of the group (p<0.001).

Conclusion. In real clinical practice, only a small part of patients with typical angina pectoris receive drug therapy that corresponds to evidence-based medicine; therefore, the unique possibilities of antianginal (anti-ischemic) therapy often remain unrealized.

1. Daly C.A., De Stavola B., Sendon J.L., et al. Euro Heart Survey Investigators. Predicting prognosis in stable angina-results from the Euro heart survey of stable angina: prospective observational study. BMJ 2006;332:262-267. DOI:10.1136/bmj.38695.605440

2. Ibanez B., James S., Agewall S., et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. agosto 2017. Eur Heart J. 2018;39(2):119-77. DOI:10.1093/eurheartj/ehx393.

3. Collet J.P., Thiele H., Barbato E., et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2020 Aug 29:ehaa575. DOI:10.1093/eurheartj/ehaa575.

4. Lee H.Y., Cooke C.E., Robertson T.A. Use of secondary prevention drug therapy in patients with acute coronary syndrome after hospital discharge. J Manag Care Pharm. 2008; 14(3): 271-80. DOI:10.18553/jmcp.2008.14.3.271

5. Martsevich S.Y., Kutishenko N.P., Kalaydzhyan E.P., et al. Assessment of the Adequacy of Drug Choice in Patients with Acute Myocardial Infarction According to the PROFILE-IM Registry. Rational Pharmacotherapy in Cardiology 2019;15(2):224-9 (In Russ.) DOI:10.20996/1819-6446-2019-15-2-224-229.

6. Knuuti J., Wijns W., Saraste A., et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes: The Task Force for the diagnosis and management of chronic coronary syndromes of the European Society of Cardiology (ESC). Eur Heart J. 2020;41(3):407-77. DOI:10.1093/eurheartj/ehz425.

7. Komajda M., Weidinger F., Kerneis M., et al. EURObservational Research Programme: the Chronic Ischaemic Cardiovascular Disease Registry: Pilot phase (CICD-PILOT) Eur Heart J. 2016;37:152-60. DOI:10.1093/eurheartj/ehv437.

8. Martsevich S.Yu., Kutishenko N.P., Sichinava D.P., et al. Prospective outpatient tregistry of myocardial infarction patients (PROFILE-MI): study design and first results. Cardiovascular Therapy and Prevention. 2018;17(1):81-6 (In Russ.) DOI:10.15829/1728-8800-2018-1-81-86.

9. Diamond G.A. A clinically relevant classification of chest discomfort. J Am Coll Cardiol. 1983;1:574- 5. DOI:10.1016/s0735-1097(83)80093-x.

10. Maddox T.M., Reid K.J., Spertus J.A., et al. Angina at 1 year after myocardial infarction. Arch Intern Med. 2008;168:1310-6. DOI:10.1001/archinte.168.12.1310.

11. Myasnikov L.A., Metelitsa V.I. Differentiated treatment of chronic ischemic heart disease. Moscow: Medicina, 1974 (In Russ.)

12. Metelitsa V.I., Kokurina E.V., Bochkareva E.V. Individual choice of antianginal drugs using paired veloergometric tests in patients with angina pectoris. Ter Arkhiv. 1992;64(9):35-9 (In Russ.)

13. Metelitsa V.I., Kokurina E.V., Martsevich S.Y. Individual choice and long-term administration of the antianginal drugs for secondary prevention of ischemic heart disease: problems, new approaches. Sov. Med. Rev. A. Cardiology. 1991;3:111-34.

14. IONA Study Group. Effect of nicorandil on coronary events in patients with stable angina: the Impact Of Nicorandil in Angina (IONA) randomised trial. Lancet. 2002;359:1269-75. DOI:10.1016/S0140-6736(02)08265-X.

15. Maron D.J., Hochman J.S., Reynolds H.R., et al. for the ISCHEMIA Research Group. Initial Invasive or Conservative Strategy for Stable Coronary Disease. N Engl J Med. 2020;382:1395-407. DOI:10.1056/NEJMoa1915922.